Study of CRD3874-SI for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh at least 88 pounds (40 kg).
- Your leukemia has come back after treatment or has not responded to at least one prior therapy.
- You are generally well enough to carry out daily activities (ECOG score 0-2).
- Your liver, kidney, and heart function test results are within an acceptable range.
- You do not have an active infection, serious heart condition, or uncontrolled graft-versus-host disease.
- You are willing to use effective contraception during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.